GLP-1 Antibody [B23D23]

Catalog No.: F1621

Application: Reactivity: Mouse, Human

Immunohistochemical analysis of formalin fixed paraffin embedded human pancreas tissue with F1621 at 1:500 dilution. ,
Immunohistochemical analysis of formalin fixed paraffin embedded human pancreas tissue with F1621 at 1:500 dilution.,

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
IHC1:2000

Application
IHC, sELISA

Source
Mouse Monoclonal Antibody

Reactivity
Mouse, Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

ポジティブコントロール	Human pancreas tissue; Diabetic mice pancreas tissue
ネガティブコントロール

プロトコール

IHC
Experimental Protocol： Deparaffinization/Rehydration 1. Deparaffinize/hydrate sections: 2. Incubate sections in three washes of xylene for 5 min each. 3. Incubate sections in two washes of 100% ethanol for 10 min each. 4. Incubate sections in two washes of 95% ethanol for 10 min each. 5. Wash sections two times in dH2O for 5 min each. 6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min. Staining 1. Wash sections in dH2O three times for 5 min each. 2. Incubate sections in 3% hydrogen peroxide for 10 min. 3. Wash sections in dH2O two times for 5 min each. 4. Wash sections in wash buffer for 5 min. 5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature. 6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C. 7. Remove antibody solution and wash sections with wash buffer three times for 5 min each. 8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature. 9. Wash sections three times with wash buffer for 5 min each. 10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use. 11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity. 12. Immerse slides in dH2O. 13. If desired, counterstain sections with hematoxylin. 14. Wash sections in dH2O two times for 5 min each. 15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each. 16. Mount sections with coverslips and mounting medium.

IHC

Experimental Protocol：

Deparaffinization/Rehydration

1. Deparaffinize/hydrate sections:

2. Incubate sections in three washes of xylene for 5 min each.

3. Incubate sections in two washes of 100% ethanol for 10 min each.

4. Incubate sections in two washes of 95% ethanol for 10 min each.

5. Wash sections two times in dH2O for 5 min each.

6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.

Staining

1. Wash sections in dH2O three times for 5 min each.

2. Incubate sections in 3% hydrogen peroxide for 10 min.

3. Wash sections in dH2O two times for 5 min each.

4. Wash sections in wash buffer for 5 min.

5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.

6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.

7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.

8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.

9. Wash sections three times with wash buffer for 5 min each.

10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.

11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.

12. Immerse slides in dH2O.

13. If desired, counterstain sections with hematoxylin.

14. Wash sections in dH2O two times for 5 min each.

15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.

16. Mount sections with coverslips and mounting medium.

Datasheet & SDS

生物学的記述

Specificity
GLP-1 Antibody [B23D23] recognizes endogenous levels of total GLP-1 protein.

タンパク質の局在
細胞外環境

Uniprot ID
P01275

Clone
B23D23

Synonym(s)
Pro-glucagon, GCG

Background
Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone primarily secreted by intestinal L-cells in response to nutrient ingestion, produced through the enzymatic cleavage of the proglucagon precursor. GLP-1 contains a conserved N-terminal sequence critical for receptor activation, including key residues such as His7 that are essential for binding and signaling, and adopts α-helical conformations stabilizing its interaction with the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed in pancreatic β-cells, brain, gastrointestinal tract, and other tissues. Upon binding GLP-1R, the receptor activates G-proteins that stimulate adenylate cyclase, increasing intracellular cAMP, which triggers downstream effectors like protein kinase A (PKA) and Epac2, enhancing glucose-dependent insulin secretion, inhibiting glucagon release mainly via somatostatin secretion from δ-cells, and slowing gastric emptying to control postprandial glucose levels. GLP-1 also reduces appetite and promotes satiety via central nervous system pathways. GLP-1R activation exerts neuroprotective effects by modulating inflammation and promoting neuronal survival through cAMP/PKA and ERK signaling pathways. Additionally, GLP-1 influences mitochondrial function and energy metabolism in muscle and neuronal cells and favors bone formation by modulating the osteoprotegerin (OPG)/RANKL ratio to support skeletal health. Endogenously, GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), limiting its half-life to about 1–2 minutes, prompting the development of GLP-1 receptor agonists and DPP-4 inhibitors as therapeutics for type 2 diabetes and obesity.

Background

Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone primarily secreted by intestinal L-cells in response to nutrient ingestion, produced through the enzymatic cleavage of the proglucagon precursor. GLP-1 contains a conserved N-terminal sequence critical for receptor activation, including key residues such as His7 that are essential for binding and signaling, and adopts α-helical conformations stabilizing its interaction with the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed in pancreatic β-cells, brain, gastrointestinal tract, and other tissues. Upon binding GLP-1R, the receptor activates G-proteins that stimulate adenylate cyclase, increasing intracellular cAMP, which triggers downstream effectors like protein kinase A (PKA) and Epac2, enhancing glucose-dependent insulin secretion, inhibiting glucagon release mainly via somatostatin secretion from δ-cells, and slowing gastric emptying to control postprandial glucose levels. GLP-1 also reduces appetite and promotes satiety via central nervous system pathways. GLP-1R activation exerts neuroprotective effects by modulating inflammation and promoting neuronal survival through cAMP/PKA and ERK signaling pathways. Additionally, GLP-1 influences mitochondrial function and energy metabolism in muscle and neuronal cells and favors bone formation by modulating the osteoprotegerin (OPG)/RANKL ratio to support skeletal health. Endogenously, GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), limiting its half-life to about 1–2 minutes, prompting the development of GLP-1 receptor agonists and DPP-4 inhibitors as therapeutics for type 2 diabetes and obesity.

References
[1] Donnelly D. Br J Pharmacol. 2012 May;166(1):27-41. [2] Zheng Z, et al. Signal Transduct Target Ther. 2024 Sep 18;9(1):234.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%